Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For inclusion in the study, patients should fulfill the following criteria:
Aged at least 18 years
Documented evidence of Stage IV NSCLC
No activating EGFR mutation or ALK rearrangement
No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC
World Health Organization (WHO) Performance Status of 0 or 1
No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines
You may not be if
Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant
Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment.
Active or prior documented autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)
Clareo Health | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
